Guardian Pharmacy Services (GRDN) Stock Price, News & Analysis

Company Overview

Guardian Pharmacy Services, Inc., a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company's Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs. The company was founded in 2003 and is based in Atlanta, Georgia.

Key Stats

• Today's Range: $23.89 to $25.01
• 50-Day Range: $19.84 to $30.24
• 52-Week Range: $16.50 to $30.39
• Volume: 183,604 shs
• Average Volume: 411,215 shs
• Market Capitalization: $1.51 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $26.33
• Consensus Rating: Moderate Buy

Guardian Pharmacy Services Stock Analysis - MarketRank™

Guardian Pharmacy Services scored higher than 25% of companies evaluated by MarketBeat, and ranked 825th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Guardian Pharmacy Services has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Guardian Pharmacy Services has a consensus price target of $26.33, representing about 10.1% upside from its current price of $23.92.

Amount of Analyst Coverage

Guardian Pharmacy Services has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: -3.45%

Earnings Growth

Earnings for Guardian Pharmacy Services are expected to decrease by -3.45% in the coming year, from $0.87 to $0.84 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Guardian Pharmacy Services is -15.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Guardian Pharmacy Services is -15.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Guardian Pharmacy Services has a P/B Ratio of 10.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.78% of the float of Guardian Pharmacy Services has been sold short.

Short Interest Ratio / Days to Cover

Guardian Pharmacy Services has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Guardian Pharmacy Services has recently increased by 58.20%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Guardian Pharmacy Services does not currently pay a dividend.

Dividend Growth

Guardian Pharmacy Services does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.78% of the float of Guardian Pharmacy Services has been sold short.

Short Interest Ratio / Days to Cover

Guardian Pharmacy Services has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Guardian Pharmacy Services has recently increased by 58.20%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.8 / 5
• News Sentiment: 0.27

News Sentiment

Guardian Pharmacy Services has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 13 news articles for Guardian Pharmacy Services this week, compared to 3 articles on an average week.

Search Interest

Only 1 people have searched for GRDN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Guardian Pharmacy Services insiders have not sold or bought any company stock.

Percentage Held by Insiders

63.71% of the stock of Guardian Pharmacy Services is held by insiders. A high percentage of insider ownership can be a sign of company health.

GRDN Stock Analysis - Frequently Asked Questions

How have GRDN shares performed this year?

Guardian Pharmacy Services' stock was trading at $20.26 at the beginning of the year. Since then, GRDN stock has increased by 18.0% and is now trading at $23.9150.

How were Guardian Pharmacy Services' earnings last quarter?

Guardian Pharmacy Services, Inc. (NYSE:GRDN) released its quarterly earnings results on Monday, May, 12th. The company reported $0.21 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.22 by $0.01. The firm earned $329.31 million during the quarter, compared to analyst estimates of $321.21 million. Guardian Pharmacy Services had a negative net margin of 6.90% and a negative trailing twelve-month return on equity of 52.41%.
Read the conference call transcript.

When did Guardian Pharmacy Services IPO?

Guardian Pharmacy Services (GRDN) raised $102 million in an initial public offering on Thursday, September 26th 2024. The company issued 6,800,000 shares at a price of $14.00-$16.00 per share. Raymond James, Stifel and Truist Securities served as the underwriters for the IPO.

How do I buy shares of Guardian Pharmacy Services?

Shares of GRDN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Guardian Pharmacy Services own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Guardian Pharmacy Services investors own include UnitedHealth Group (UNH) and Meta Platforms (META).

Company Calendar

• Last Earnings: 5/12/2025
• Today: 10/06/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Retail
• Current Symbol: NYSE:GRDN
• Previous Symbol: NYSE:GRDN
• CIK: 1802255
• Web: guardianpharmacy.com
• Phone: (404) 810-0089
• Fax: N/A
• Employees: 3,400
• Year Founded: 2004

Price Target and Rating

• Average Price Target for Guardian Pharmacy Services: $26.33
• High Price Target: $30.00
• Low Price Target: $21.00
• Potential Upside/Downside: +10.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.52)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 27.49
• P/E Growth: N/A
• Net Income: -$87.29 million
• Net Margins: -6.90%
• Pretax Margin: -4.80%
• Return on Equity: -52.41%
• Return on Assets: -24.17%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.18
• Quick Ratio: 0.88

Sales & Book Value

• Annual Sales: $1.23 billion
• Price / Sales: 1.23
• Cash Flow: $0.25 per share
• Price / Cash Flow: 95.98
• Book Value: $2.37 per share
• Price / Book: 10.09

Miscellaneous

• Outstanding Shares: 63,320,000
• Free Float: 22,979,000
• Market Cap: $1.51 billion
• Optionable: N/A
• Beta: N/A